Mustang Bio Management
Management criteria checks 4/4
Mustang Bio's CEO is Manny Litchman, appointed in Apr 2017, has a tenure of 7.17 years. total yearly compensation is $501.84K, comprised of 95.8% salary and 4.2% bonuses, including company stock and options. directly owns 0.32% of the company’s shares, worth $8.04K. The average tenure of the management team and the board of directors is 2.3 years and 8 years respectively.
Key information
Manny Litchman
Chief executive officer
US$501.8k
Total compensation
| CEO salary percentage | 95.8% |
| CEO tenure | 7.2yrs |
| CEO ownership | 0.3% |
| Management average tenure | 2.3yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Mustang Bio: This Horse May Gallop Still
Sep 23Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?
Aug 09
Mustang Bio: The Market Is Missing This Opportunity
May 03Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
Dec 29Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Sep 14Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
Jun 18Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Jun 11Checking Back In On Mustang Bio
May 26FDA accepts Mustang Bio's MB-106 application in cancer
May 10Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
Mar 22What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?
Feb 23Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price
Jan 28
Mustang Bio launches early-stage CAR T therapy study in brain tumor
Dec 21Lindsay Rosenwald Is The Non-Executive Director of Mustang Bio, Inc. (NASDAQ:MBIO) And They Just Picked Up 100% More Shares
Dec 18Mustang Bio gains after impressing with ASH presentation
Dec 07Is Mustang Bio (NASDAQ:MBIO) In A Good Position To Invest In Growth?
Dec 04Mustang Bio EPS beats by $0.02
Nov 06CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$40m |
| Dec 31 2023 | US$502k | US$481k | -US$52m |
| Sep 30 2023 | n/a | n/a | -US$63m |
| Jun 30 2023 | n/a | n/a | -US$72m |
| Mar 31 2023 | n/a | n/a | -US$74m |
| Dec 31 2022 | US$636k | US$448k | -US$78m |
| Sep 30 2022 | n/a | n/a | -US$78m |
| Jun 30 2022 | n/a | n/a | -US$76m |
| Mar 31 2022 | n/a | n/a | -US$71m |
| Dec 31 2021 | US$885k | US$450k | -US$66m |
| Sep 30 2021 | n/a | n/a | -US$67m |
| Jun 30 2021 | n/a | n/a | -US$63m |
| Mar 31 2021 | n/a | n/a | -US$63m |
| Dec 31 2020 | US$1m | US$430k | -US$60m |
| Sep 30 2020 | n/a | n/a | -US$56m |
| Jun 30 2020 | n/a | n/a | -US$53m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$517k | US$415k | -US$46m |
| Sep 30 2019 | n/a | n/a | -US$42m |
| Jun 30 2019 | n/a | n/a | -US$39m |
| Mar 31 2019 | n/a | n/a | -US$34m |
| Dec 31 2018 | US$606k | US$403k | -US$31m |
| Sep 30 2018 | n/a | n/a | -US$34m |
| Jun 30 2018 | n/a | n/a | -US$34m |
| Mar 31 2018 | n/a | n/a | -US$34m |
| Dec 31 2017 | US$6m | US$267k | -US$31m |
Compensation vs Market: Manny's total compensation ($USD501.84K) is about average for companies of similar size in the US market ($USD667.49K).
Compensation vs Earnings: Manny's compensation has been consistent with company performance over the past year.
CEO
Manny Litchman (70 yo)
7.2yrs
Tenure
US$501,838
Compensation
Dr. Manuel Litchman, also known as Manny, M.D. has been the President, Chief Executive Officer and Director at Mustang Bio, Inc. since April 24, 2017 and served as Interim Chief Financial Officer since Dec...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.1yrs | US$110.00k | 0.13% $ 3.3k | |
| President | 7.2yrs | US$501.84k | 0.32% $ 8.0k | |
| Interim Chief Financial Officer | less than a year | no data | no data | |
| Controller & Interim Chief Accounting Officer | less than a year | no data | 0.020% $ 505.3 | |
| VP & General Counsel | 2.8yrs | no data | no data | |
| Senior VP & Head of Human Resources | 5.4yrs | no data | no data | |
| VP & Head of Regulatory Affairs | 4.3yrs | no data | no data | |
| Senior VP & Head of Clinical Development | 3yrs | no data | no data | |
| Chief Quality Officer | 1.4yrs | no data | no data | |
| Head of CMC Development | 1.8yrs | no data | no data | |
| VP and Head of Program & Alliance Leadership | 1.4yrs | no data | no data | |
| VP & Head of Clinical Operations | 1.4yrs | no data | no data |
2.3yrs
Average Tenure
62.5yo
Average Age
Experienced Management: MBIO's management team is considered experienced (2.3 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Executive Chairman | 9.1yrs | US$110.00k | 0.13% $ 3.3k | |
| President | 7.2yrs | US$501.84k | 0.32% $ 8.0k | |
| Non-Executive Director | 9.3yrs | US$100.00k | 0.22% $ 5.5k | |
| Independent Director | 7yrs | US$100.00k | 0.15% $ 3.8k | |
| Independent & Non-Executive Director | 8.8yrs | US$100.00k | 0.16% $ 4.0k | |
| Independent Director | 7yrs | US$110.00k | 0.15% $ 3.9k |
8.0yrs
Average Tenure
65.5yo
Average Age
Experienced Board: MBIO's board of directors are considered experienced (8 years average tenure).